FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313412059> ?p ?o ?g. }

• W4313412059 abstract "Background and Aims Protein convertase subtilisin/Kexin type 9 monoclonal antibodies (PCSK9mab) are a novel addition to the therapeutic options for managing hyperlipidemia. Various guidelines have advocated the addition of these agents if the target low-density lipoprotein-cholesterol ( LDL-C) is not achieved by maximum lipid-lowering therapy. They have shown a robust and consistent reduction in LDL-C in clinical trials. However, the translation of these results in a real-world setting is limited and confined mainly to tertiary lipid centers. This service evaluation aimed to assess their efficacy in a real-world outpatient setting of secondary care centers. Methods Data was collected retrospectively from four hospitals in the North-West of England. Patients were required to attend a lipid clinic for follow-up investigations to continue with the prescription of PCSK9mab. Results A total of 175 patients were identified. Efficacy outcomes were measured in 169 patients. 6 discontinued the agent within 3 months of initiation and were excluded from the efficacy outcomes. 19.5% (n=33) had confirmed familial hypercholesterolemia. 61% (n=103) of the patients were intolerant to statins. 53.2% (n=90) of the patients have been prescribed Alirocumab. Mean LDL-C reduction was 50.6% at 6-month which was sustained at 48.9% at 12 months. There was no difference in % reduction of LDL-C between Alirocumab and Evolocumab. LDL-C reduction was more significant in patients who were on concomitant statins. 9.1% of patients experienced side effects, and 5.1% discontinued the PCSK9mab during treatment. Conclusion The efficacy of lipid reduction and the side effect profile of PCSK9mab from these secondary care services are similar to randomized clinical trials and real-world observational studies from tertiary lipid centers." @default.
• W4313412059 created "2023-01-06" @default.
• W4313412059 creator A5007158086 @default.
• W4313412059 creator A5017886372 @default.
• W4313412059 creator A5018532917 @default.
• W4313412059 creator A5025576102 @default.
• W4313412059 creator A5025751385 @default.
• W4313412059 creator A5026127379 @default.
• W4313412059 creator A5029885535 @default.
• W4313412059 creator A5036967159 @default.
• W4313412059 creator A5044475813 @default.
• W4313412059 creator A5064426532 @default.
• W4313412059 date "2022-12-28" @default.
• W4313412059 modified "2023-09-26" @default.
• W4313412059 title "Protein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies (PCSK9mab) in Clinical Practice at Secondary Care – Real World Multicentre Experience" @default.
• W4313412059 cites W1423581981 @default.
• W4313412059 cites W1533985811 @default.
• W4313412059 cites W1607804102 @default.
• W4313412059 cites W2101185950 @default.
• W4313412059 cites W2101455935 @default.
• W4313412059 cites W2118184073 @default.
• W4313412059 cites W2120729896 @default.
• W4313412059 cites W2314193179 @default.
• W4313412059 cites W2396620104 @default.
• W4313412059 cites W2594072057 @default.
• W4313412059 cites W2596179513 @default.
• W4313412059 cites W2608952308 @default.
• W4313412059 cites W2609543937 @default.
• W4313412059 cites W2762069281 @default.
• W4313412059 cites W2774009850 @default.
• W4313412059 cites W2776910835 @default.
• W4313412059 cites W2806550872 @default.
• W4313412059 cites W2899997727 @default.
• W4313412059 cites W2941101173 @default.
• W4313412059 cites W2953804067 @default.
• W4313412059 cites W2989910051 @default.
• W4313412059 cites W3033787656 @default.
• W4313412059 cites W3080919444 @default.
• W4313412059 cites W3183857127 @default.
• W4313412059 cites W4239175672 @default.
• W4313412059 doi "https://doi.org/10.7759/cureus.33044" @default.
• W4313412059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36721583" @default.
• W4313412059 hasPublicationYear "2022" @default.
• W4313412059 type Work @default.
• W4313412059 citedByCount "0" @default.
• W4313412059 crossrefType "journal-article" @default.
• W4313412059 hasAuthorship W4313412059A5007158086 @default.
• W4313412059 hasAuthorship W4313412059A5017886372 @default.
• W4313412059 hasAuthorship W4313412059A5018532917 @default.
• W4313412059 hasAuthorship W4313412059A5025576102 @default.
• W4313412059 hasAuthorship W4313412059A5025751385 @default.
• W4313412059 hasAuthorship W4313412059A5026127379 @default.
• W4313412059 hasAuthorship W4313412059A5029885535 @default.
• W4313412059 hasAuthorship W4313412059A5036967159 @default.
• W4313412059 hasAuthorship W4313412059A5044475813 @default.
• W4313412059 hasAuthorship W4313412059A5064426532 @default.
• W4313412059 hasBestOaLocation W43134120591 @default.
• W4313412059 hasConcept C126322002 @default.
• W4313412059 hasConcept C134018914 @default.
• W4313412059 hasConcept C2778114629 @default.
• W4313412059 hasConcept C2778163477 @default.
• W4313412059 hasConcept C2778849439 @default.
• W4313412059 hasConcept C2779091943 @default.
• W4313412059 hasConcept C2779120738 @default.
• W4313412059 hasConcept C2779384505 @default.
• W4313412059 hasConcept C2780072125 @default.
• W4313412059 hasConcept C2780745583 @default.
• W4313412059 hasConcept C2780902209 @default.
• W4313412059 hasConcept C2780948078 @default.
• W4313412059 hasConcept C43554185 @default.
• W4313412059 hasConcept C555293320 @default.
• W4313412059 hasConcept C71924100 @default.
• W4313412059 hasConceptScore W4313412059C126322002 @default.
• W4313412059 hasConceptScore W4313412059C134018914 @default.
• W4313412059 hasConceptScore W4313412059C2778114629 @default.
• W4313412059 hasConceptScore W4313412059C2778163477 @default.
• W4313412059 hasConceptScore W4313412059C2778849439 @default.
• W4313412059 hasConceptScore W4313412059C2779091943 @default.
• W4313412059 hasConceptScore W4313412059C2779120738 @default.
• W4313412059 hasConceptScore W4313412059C2779384505 @default.
• W4313412059 hasConceptScore W4313412059C2780072125 @default.
• W4313412059 hasConceptScore W4313412059C2780745583 @default.
• W4313412059 hasConceptScore W4313412059C2780902209 @default.
• W4313412059 hasConceptScore W4313412059C2780948078 @default.
• W4313412059 hasConceptScore W4313412059C43554185 @default.
• W4313412059 hasConceptScore W4313412059C555293320 @default.
• W4313412059 hasConceptScore W4313412059C71924100 @default.
• W4313412059 hasLocation W43134120591 @default.
• W4313412059 hasLocation W43134120592 @default.
• W4313412059 hasLocation W43134120593 @default.
• W4313412059 hasOpenAccess W4313412059 @default.
• W4313412059 hasPrimaryLocation W43134120591 @default.
• W4313412059 hasRelatedWork W2046996117 @default.
• W4313412059 hasRelatedWork W2162657286 @default.
• W4313412059 hasRelatedWork W2332869708 @default.
• W4313412059 hasRelatedWork W2344543776 @default.
• W4313412059 hasRelatedWork W2466623256 @default.
• W4313412059 hasRelatedWork W2585426472 @default.
• W4313412059 hasRelatedWork W2620969414 @default.
• W4313412059 hasRelatedWork W2752864344 @default.

• next